share_log

Predictmedix Receives Purchase Order Valued at $500k From MGM Healthcare for AI-Powered Safe Entry Stations to Enhance Healthcare Operations

Predictmedix Receives Purchase Order Valued at $500k From MGM Healthcare for AI-Powered Safe Entry Stations to Enhance Healthcare Operations

Predictmedix从米高梅医疗收到价值50万美元的采购订单,购买由人工智能驱动的安全进入站以加强医疗运营
Accesswire ·  2023/03/30 19:10

TORONTO, ON / ACCESSWIRE / March 30, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), today announced a purchase order from one of the largest Government hospital groups in India, MGM Healthcare, for the company's AI-powered Safe Entry Stations. The purchase order was followed by the recently completed third-party, 400-patient clinical study conducted by MGM Healthcare in which the scope was to determine the effectiveness of Predictmedix's AI-powered screening technology.

安大略省多伦多/ACCESSWIRE/2023 年 3 月 30 日/ Predictmedix Inc.(“Predicmedix” 或 “公司”) (CSE: PMED) (OTCQB: PMEDF) (FRA: 3QP)由专有人工智能(AI)提供支持的快速健康筛查解决方案的领先提供商,今天宣布从印度最大的政府医院集团之一米高梅医疗公司订购该公司的人工智能安全进入站。在下达采购订单后,米高梅医疗最近完成了由400名患者组成的第三方临床研究,其范围是确定Predictmedix的人工智能筛查技术的有效性。

Safe Entry is a comprehensive and global risk management solution that utilizes a fully patented system to rapidly and autonomously screen for individuals' key vitals. The Safe Entry Station is a walk-thru system where an individual stands in front of the unit for 2-3 seconds while multi-spectral imaging cameras gather the necessary information to determine the physiological state of an individual. Parameters like temperature, heart rate, and respiration rate are collected non-invasively and the AI/ML algorithms compute a result. Vitals hold key insight into an individual's state, whether they're dealing with health complications, influenza, fatigue or even impairment. Safe Entry does not capture or store personal identity information, ever.

Safe Entry是一种全面的全球风险管理解决方案,它利用完全专利的系统来快速、自主地筛查个人的关键要素。Safe Entry Station 是一个步行式系统,一个人站在设备前面 2-3 秒,而多光谱成像摄像机则收集必要的信息,以确定个人的生理状态。温度、心率和呼吸频率等参数是非侵入性收集的,AI/ML 算法计算结果。Vitals是了解个人状态的关键见解,无论他们是在治疗健康并发症、流感、疲劳还是损伤。Safe Entry 永远不会捕获或存储个人身份信息。

MGM Healthcare is a prominent group of medical universities in India, comprising multiple hospitals across the country. Known for their state-of-the-art facilities and commitment to delivering exceptional healthcare services, MGM Healthcare has chosen to deploy five Safe Entry Stations to screen patients for infectious diseases and triage purposes. This purchase order represents a substantial investment, with a value of approximately $500,000 CAD spread over a three-year period. By choosing to implement Predictmedix's AI-powered screening technology, MGM Healthcare is demonstrating its commitment to providing innovative solutions that improve patient outcomes and enhance the efficiency of healthcare operations.

MGM Healthcare是印度著名的医科大学集团,由全国多家医院组成。MGM Healthcare以其最先进的设施和致力于提供卓越的医疗服务而闻名,已选择部署五个安全入境站,对患者进行传染病筛查和分诊。该采购订单是一项巨额投资,价值约为50万加元,为期三年。通过选择实施Predicmedix的人工智能筛查技术,MGM Healthcare表明了其致力于提供创新解决方案以改善患者预后和提高医疗运营效率的承诺。

Aside from providing a quick and effective method of screening for impairment and infectious diseases, Safe Entry's AI-powered technology also helps healthcare facilities overcome staffing challenges. With limited resources, hospitals need to ensure that their staff is being utilized in the most efficient way possible. By quickly analyzing an individual's vital signs, Safe Entry can reduce wait times and processing times for patients, enabling healthcare providers to focus on providing timely care to patients who need it most. This non-invasive method of collecting vitals is more comfortable for patients, which can lead to a better overall patient experience. By improving patient care and streamlining operations, Safe Entry offers a comprehensive solution for healthcare facilities looking to enhance their capabilities.

除了提供一种快速有效的损伤和传染病筛查方法外,Safe Entry的人工智能技术还可以帮助医疗机构克服人员配备方面的挑战。在资源有限的情况下,医院需要确保尽可能有效地利用其员工。通过快速分析个人的生命体征,Safe Entry可以减少患者的等待时间和处理时间,使医疗保健提供者能够专注于为最需要治疗的患者提供及时的护理。这种非侵入性生命体征采集方法对患者来说更舒适,可以带来更好的整体患者体验。通过改善患者护理和简化运营,Safe Entry 为希望增强能力的医疗机构提供了全面的解决方案。

"With over 69,000 hospitals in India alone, having our footing in the healthcare space is a major achievement for Predictmedix. This positions us to unlock immense opportunities for expanding our cutting-edge healthcare technology in South Asia and ASEAN countries. South Asia and ASEAN countries present a substantial opportunity for Predictmedix to enhance healthcare in regions with large populations. Furthermore, our technology has shown promising results with the recently completed 1600-person clinical study at an Indonesian University.We strongly believe our innovative tech can play a crucial role in improving healthcare outcomes and easing the burden on healthcare systems, and we look forward to expanding our presence in these regions," stated Dr. Rahul Kushwah, COO at Predictmedix."

“仅在印度就有超过69,000家医院,我们在医疗保健领域站稳脚跟是Predictmedix的一项重大成就。这使我们能够释放巨大的机会,在南亚和东盟国家扩展我们的尖端医疗保健技术。南亚和东盟国家为Predictmedix提供了在人口众多地区加强医疗保健的巨大机会。此外,最近在印度尼西亚一所大学完成的1600人临床研究显示,我们的技术取得了令人鼓舞的结果。我们坚信,我们的创新技术可以在改善医疗结果和减轻医疗保健系统负担方面发挥关键作用,我们期待扩大我们在这些地区的影响力,” Predictmedix首席运营官Rahul Kushwah博士说。”

"Securing a purchase order directly from MGM Healthcare is a major achievement for Predictmedix, as it validates the effectiveness and potential of our technology in the healthcare sector. Our team has been dedicated to commercializing this technology for some time, and the fact that MGM Healthcare has conducted third-party clinical studies with Safe Entry further underscores the confidence in our product. We are excited to continue partnering with MGM Healthcare to provide state-of-the-art healthcare solutions to patients across India," commented Guru Bakshish Singh Sehgal, Head of Indian Operations at Predictmedix.

“直接从MGM Healthcare获得采购订单是Predictmedix的一项重大成就,因为它验证了我们的技术在医疗保健领域的有效性和潜力。我们的团队致力于将这项技术商业化已有一段时间,而MGM Healthcare已通过Safe Entry进行了第三方临床研究,这一事实进一步凸显了人们对我们产品的信心。我们很高兴能继续与米高梅医疗合作,为印度各地的患者提供最先进的医疗保健解决方案。” Predictmedix印度运营主管Guru Bakshish Singh Sehgal评论道。

About Predictmedix Inc.

关于 Predicmedix Inc.

Predictmedix (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Predictmedix(CSE: PMED)(OTCQB: PMEDF)(FRA: 3QP)是全球快速健康筛查和远程患者护理解决方案的新兴提供商。该公司的安全进入站由专有的人工智能(AI)提供支持,使用多光谱摄像机分析生理数据模式并预测各种健康问题,包括 COVID-19 等传染病、药物或酒精损伤、疲劳或各种精神疾病。Predictmedix 专有的远程患者护理平台为医疗专业人员提供了一套人工智能驱动的工具,以改善患者的健康状况。要了解更多信息,请访问我们的网站或在推特、Instagram 或 LinkedIn 上关注我们。

Public Relations Contact
For further media information or to set up an interview, please contact:

公共关系联系人
欲了解更多媒体信息或安排采访,请联系:

Nelson Hudes
Hudes Communications International
(905) 660 9155
Nelson@hudescommunications.com

纳尔逊·哈德斯
Hudes 通讯国际
(905) 660 9155
Nelson@hudescommunications.com

Dr. Rahul Kushwah
(647) 889 6916

拉胡尔·库什瓦博士
(647) 889 6916

Caution Regarding Forward-Looking Information:

关于前瞻性信息的注意事项:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

本新闻稿可能包含前瞻性陈述和基于当前预期的信息。这些陈述不应被视为对公司未来业绩或业绩的保证。此类陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致实际业绩、业绩或成就与此类陈述所暗示的结果存在重大差异。尽管此类陈述基于管理层的合理假设,但无法保证此类假设会被证明是正确的。我们不负责更新或修改它们以反映新的事件或情况。公司的证券尚未根据经修订的1933年《美国证券法》(“美国证券法”)或适用的州证券法进行注册,如果没有注册或不受此类注册要求的适用豁免,则不得向在美国的人或 “美国个人”(该术语的定义见美国证券法的法规)发行或出售,也不得为他们的账户或利益发行或出售。本新闻稿不构成出售要约或招揽买入要约,也不得在美国或任何此类要约、招揽或出售非法的司法管辖区出售证券。此外,还有一些已知和未知的风险因素可能导致公司的实际业绩、业绩或成就与本文件所含前瞻性信息所表达或暗示的未来业绩、业绩或成就存在重大差异,例如但不限于依赖获得监管部门批准;获得与其技术相关的知识产权的能力;运营历史有限;一般商业、经济、竞争、政治、监管和社会不确定性,以及特别是与 COVID-19 相关的不确定性;与公司无法控制的因素相关的风险,包括与 COVID-19 相关的风险;与公司股票相关的风险,包括该方可能也可能无法控制的事件导致的价格波动;对管理层的依赖;以及该行业其他竞争对手的紧急情况。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

本文中的所有前瞻性信息均受本警示声明的全面限制,除非法律要求,否则公司不承担任何修改或更新任何此类前瞻性信息或公开宣布为反映未来业绩、事件或发展而对本文包含的任何前瞻性信息进行任何修订的结果的义务。

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."

免责声明:“公司目前没有明示或暗示地声称其产品能够诊断、消除、治愈或控制 COVID-19(或 SARS-2 冠状病毒)。”

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所尚未审查本新闻稿的充分性或准确性,也不承担任何责任。

SOURCE: PredictMedix Inc.

来源: predicmedix Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代码版本:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发